Utilidad de los fármacos modificadores de enfermedad (FAME) en el tratamiento de las espondiloartropatías

Disease-modifying antirheumatic drugs (DMARDs), a heterogeneous group of drugs, are widely used in rheumatoid arthritis management. The scientific evidence on the management of spondyloarthropathy with DMARDs is limited and the results are inconclusive. In this article, we review the role of DMARDs in the management of axial involvement in spondyloarthropathies, emphasizing its paradigm, ankylosing spondylitis. We review the data published to date on the efficacy and tolerability of salazopyrin, mesalazine, methotrexate, and leflunomide, as well as those of other drugs used on specific occasions such as pamidronate and thalidomide. Data on the effects of this management on peripheral symptoms and organic disease-like uveitis are also included.